Phytotherapy and evidence: what is established for herbal medicines
A few plant extracts are well studied, many classics only weakly. And herbal does not mean harmless. Here you will see what lies behind the German labels Zul.-Nr., Reg.-Nr. and food supplement, why a plant name does not yet describe a preparation, and how you can put studies into context yourself.
When you should stop reading and get help instead
Suicidal thoughts or the feeling that you no longer want to live: Get help immediately. In Germany, the Telefonseelsorge crisis line is available around the clock and free of charge at 0800 111 0 111 and 0800 111 0 222. In acute danger, call 112 or go to the nearest psychiatric hospital or emergency department. These are German numbers; outside Germany, please contact your local crisis line or emergency services.
Further red flags when your mood is low: self-harm, delusional symptoms, marked loss of drive lasting for weeks, significant weight loss, or when you can barely manage eating, drinking and personal care. This belongs promptly in medical or psychotherapeutic hands, not in a herbal preparation.
Liver warning signs while taking a herbal remedy: yellowing of the skin or eyes, dark urine, pale stools, pain in the upper abdomen, unusual tiredness. Please have this checked by a doctor promptly and name the preparation.
Unusual bleeding or bruising while taking anticoagulants plus a herbal preparation: have it checked by a doctor.
Restlessness, fever, sweating, tremor or confusion when St John's wort is combined with an antidepressant: this can point to serotonin syndrome. Get medical help immediately, and in a severe state call 112.
You are standing in a pharmacy. In front of you are two boxes, both showing the same plant. One says “Zul.-Nr.” in small print, the German marketing authorization number. The other says “Reg.-Nr.”, a registration number, together with a sentence about long-standing use. In the drugstore around the corner there is a capsule with the same name, labeled as a food supplement.
Herbal sounds gentle. Safe. Like something you can simply try. Many people know this pattern, and many are surprised that a herb from the pharmacy shelf can contribute to a transplant rejection.
I want to look with you at what is established for herbal medicines. Where guidelines say yes, where maybe and where no. And how you can tell whether a pack stands for a tested benefit, a long tradition or a food.
This article is not a reason to change any treatment
No prescribed medicine is stopped, reduced or replaced by a herbal remedy because of this article. That applies to antidepressants, anti-anxiety medicines, sleeping pills, anticoagulants, immunosuppressants, hormonal contraception, thyroid hormones, HIV and cancer medicines, just as it does to prostate medicines or hormone therapy during menopause.
Antidepressants: Stopping abruptly carries its own risks. Any change belongs in the hands of the prescribing doctor.
Sleeping pills, benzodiazepines and Z-drugs: After longer use, stopping abruptly can be dangerous, up to and including seizures. Any tapering belongs under medical supervision.
Ending a St John's wort preparation also changes something. According to the EU monograph, the increased enzyme activity returns to baseline within one week, and the levels of other medicines can shift. This, too, needs to be discussed with a doctor.
Herbal remedies belong on every medication list, including teas, drops and capsules, especially before a planned operation.
Herbal medicines are not a gentle side branch of medicine. They are medicines. A small number of precisely defined extracts have a well-founded place in good studies and guidelines. Many popular herbal preparations do not, and all of them can have side effects and interactions.
What to expect here
- Zul.-Nr., Reg.-Nr., food supplement: three routes onto the shelf
- Why two preparations of the same plant are not the same
- St John's wort, peppermint oil, lavender, ginkgo: evidence and limits
- Pelargonium, echinacea, valerian, saw palmetto, black cohosh
- Interactions, pregnancy, liver
- Adulteration, heavy metals, pyrrolizidine alkaloids
- Why there are fewer large studies
- Five questions to check the evidence yourself
Animal and cell data play hardly any role here, because this is about people, preparations and guidelines. In the examples, a label shows the level on which a statement stands: Supported by meta-analyses and guidelines Mixed or disputed Mechanistically plausible, human studies thin Clinical tradition without a strong study base What I observe clinically
What phytotherapy is, and what the number on the pack tells you
“Isn't that just herbal tea and homeopathic globules?” The question is understandable. In everyday life, much of what the law separates neatly becomes blurred.
According to Section 4 (29) of the German Medicines Act (AMG), herbal medicinal products are medicines that contain “as active substances exclusively one or more herbal substances or one or more herbal preparations”. Phytopharmaceuticals is simply another word for them. In pharmacy, a herbal drug is not a narcotic but the dried plant part. An extract is made when constituents are dissolved out of this herbal drug with a solvent. The term rational phytotherapy is used when such medicines are measured against the same scientific standards as other medicines.
A distinction in one sentence: In Germany, homeopathic medicinal products can be registered without submitting information on effects and indications (§ 38 (2) AMG), and anthroposophic medicinal products are developed according to the anthroposophic understanding of the human being and nature (§ 4 (33) AMG); both are separate therapeutic approaches that this article is not about. My view of anthroposophy is set out in anthroposophic medicine put into context.
An image for it: the plant is the raw material, the extract is the medicine. As with grapes and wine, processing decides what ends up in the bottle.
Herbal describes the origin. Not the efficacy and not the safety. Both have to be shown separately for each preparation.
Three routes onto the shelf
“Both packs say St John's wort. Where is the difference?” It lies in what a manufacturer had to show before the product could be sold.
| Authorized herbal medicinal product | Traditional herbal medicinal product | Food supplement | |
|---|---|---|---|
| Labeling | Zul.-Nr. (authorization number) | Reg.-Nr. (registration number) and mandatory statement on long-standing use | no medicinal product number |
| Status | medicinal product | medicinal product, simplified registration | food |
| Efficacy | own studies or bibliographic: at least ten years of general medical use in the EU, effects and side effects known; EMA: “well-established use” | at least 30 years of medicinal use, 15 of them in the EU; efficacy must be “plausible”; according to EMA no clinical trials needed as long as sufficient safety data are available | no proof of efficacy required |
| Use | depending on the authorization, also diseases requiring medical treatment, such as prescription-only St John's wort for moderate depression | only uses without medical diagnosis or supervision; only oral, external or inhaled | mood and general health claims for plant substances inadmissible in principle according to the CJEU 2025, as long as the EU review is ongoing |
| Before sale | official authorization | official registration | only notification to the BVL, “no review or approval by an authority” |
The mandatory statement on traditional medicines is remarkably honest. According to Section 10 (4a) AMG, it must state that the product is “registered exclusively on the basis of long-standing use for the indication”. For food supplements, the German Federal Office of Consumer Protection and Food Safety (BVL) states that it carries out “no assessment, review or approval”. Companies are themselves responsible for safety, and checks are carried out afterwards by the federal states. When food supplements can make sense and when they tend to get in the way, I describe in When food supplements make sense.
Commission E and the HMPC
Commission E was founded in 1978 as an expert panel and published around 380 monographs on herbal drugs until its legal mandate to produce monographs ended after 1994. It assessed the preparations mainly on the basis of bibliographic data, as a paper by Keller already described in 1991. A positive Commission E monograph is therefore a valuable historical document, but not proof of efficacy in the sense of today's randomized trials.
Today the Committee on Herbal Medicinal Products, the HMPC at the European Medicines Agency, sets the standards. It was established in 2004 and had adopted around 120 EU monographs by early 2014. These visibly separate “well-established use” from “traditional use”, perhaps the most useful distinction of all.
Herbal does not mean non-prescription, and it is rarely covered by insurance
The German Ordinance on Prescription-Only Medicines (AMVV), for example, lists “St John's wort, for the treatment of moderate depression” and kava-kava as prescription-only. And statutory health insurance may cover non-prescription medicines only by way of exception, when they are considered the standard of care for serious diseases. This restriction does not apply to children up to their 12th birthday or to adolescents with developmental disorders up to their 18th birthday (§ 34(1) SGB V). The exception list of the Federal Joint Committee (G-BA) names, among others, a Ginkgo biloba leaf extract for this, “standardized 240 mg daily dose”, “only for the treatment of dementia”, which the S3 guideline on dementia confirms. Voluntary extra benefits offered by individual insurers are not a general rule.
The number on the pack tells you more than the picture of the plant. Zul.-Nr., Reg.-Nr. or no number at all is the simplest information about what has been checked behind a product.
And now you know why two green boxes with the same name can legally be two different things.
Why extracts are not interchangeable
“St John's wort is St John's wort, isn't it?” No. And that may be the most important idea in this article.
Imagine two cups of coffee from the same bean. One is a strong espresso, the other a thin filter coffee. Same name, different drink. With plant extracts it is similar, except that you cannot taste the difference.
Five levers between plant and preparation
- Starting material: which plant part, which origin, which quality.
- Extraction solvent: water, ethanol, methanol, oil or hexane each dissolve different constituents.
- Drug extract ratio, DER for short: how much dried plant is contained in a given amount of extract. A DER of 5:1 means that one part of extract was obtained from five parts of herbal drug.
- Duration and temperature of the extraction.
- Excipients and dosage form, which influence what is released and absorbed.
The DER alone does not fully describe an extract, because starting material, solvent, duration, temperature and excipients also play a role (Monagas 2022). Extracts are multi-component mixtures whose composition depends on manufacturing and plant material, which makes studies harder to interpret (Heinrich 2022). “Equivalent to X mg of plant” is therefore not a statement of quality.
The HMPC has adopted an EU monograph for St John's wort, most recently revised in 2022.
There, only certain dry extracts support the use for “mild to moderate depressive episodes” as “well-established use”, for example with a DER of 3-7:1 and methanol 80 % or 3-6:1 and ethanol 80 %. Oily macerates and tinctures appear only as “traditional use”, for temporary mental exhaustion or minor skin inflammation and wounds.
What this means for you: two packs can both say St John's wort, and only one of them is a preparation the depression studies refer to.
HMPC. EU herbal monograph on Hypericum perforatum L., herba. EMA/HMPC/7695/2021, Rev. 1, 2022. [Regulatory document, EMA/HMPC]Interactions also depend on the preparation. St John's wort can activate a receptor called PXR, which can ramp up breakdown enzymes such as CYP3A4 and the transport pump P-glycoprotein, and the extent is significantly related to the hyperforin content (Nicolussi 2020). The German National Disease Management Guideline describes over-the-counter St John's wort preparations as “very variable” in composition.
A group around Mueller gave 20 healthy men a St John's wort powder low in hyperforin for two weeks. Exposure to the test drug midazolam fell by an average of 11.3 percent, classified as a mild induction without clinical relevance. What this means for you: the direction fits the mechanism, but these data say nothing about people after a transplant or on the pill. A low-hyperforin preparation is no free pass.
Mueller SC et al. Eur J Clin Pharmacol. 2009;65(1):81-7. PMID: 18762932 [Human study, pharmacokinetics, n = 20]Four more examples
Lavender. The German S3 guideline on anxiety disorders discusses a specific lavender oil extract and states explicitly: “For other lavender oil extracts […] no statements can be made.”
Pelargonium. A Cochrane review found effects in acute bronchitis with the liquid preparation, but not with tablets, and refrained from pooling some results because the type of preparation created too much heterogeneity (Timmer 2013).
Saw palmetto. The Cochrane review across all extracts is negative (Franco 2023). The 2026 guideline of the European Association of Urology, by contrast, notes that only one hexane-derived extract is recognized by the HMPC as “well-established use”, points out, regarding an older Cochrane meta-analysis of 30 trials, that different brands were included in it regardless of this extract, and recommends it weakly, with the strong advice that its efficacy may only be “modest”. This rests, among other things, on a meta-analysis of this extract alone, which mixed randomized trials with observational studies and had a co-author from the manufacturer (Vela-Navarrete 2018).
Ginkgo and echinacea. Ginkgo products from the US market contained between 24 and 36 percent flavone glycosides and ginkgolic acids ranging from below 500 to about 90000 ppm, and many did not meet the German pharmacopoeial specification, so they could not be considered pharmaceutically equivalent (Kressmann 2002, US market, no statement about today's German medicines). And the Cochrane review on echinacea stresses that products sold under the name echinacea differ “appreciably in their composition” (Karsch-Völk 2014).
For some plants, absorption in the gut adds a further layer, described in detail in Curcumin and the question of absorption.
A study applies to the preparation that was tested. Not to the plant as an idea. When someone says “studies show that plant X is effective”, it is worth asking back: which preparation exactly?
And now you know why I so often write “a specific extract” instead of just the plant name.
Herbal medicines with solid evidence, and where it ends
“Are there any herbal remedies at all that demonstrably do something?” Yes, some. There are fewer than the shelves suggest, and each has a narrow indication. The table shows nine well-known examples; I discuss the first four here and the rest in the next section.
| Plant, preparation | Studied for | Guideline or assessment | Most important limitation |
|---|---|---|---|
| St John's wort, certain authorized dry extracts | mild to moderate depression | NVL 3.2: “can … be offered”, open | no data on severe depression; interactions |
| Peppermint oil, enteric-coated | irritable bowel syndrome | S3 2021: “shall be considered”, grade A | a large recent study missed its primary endpoint |
| a specific lavender oil extract | anxiety | S3 anxiety 2021: no recommendation; WFSBP: “++” | manufacturer-funded; no long-term studies |
| a standardized ginkgo extract | mild to moderate dementia | S3 dementia 2023: “We suggest”, weak | no effect in mild cognitive impairment and in prevention |
| Pelargonium, liquid | acute bronchitis, colds | DEGAM: benefit-harm “not conclusively” assessable | low evidence; liver warning |
| Echinacea | colds | Cochrane: no proven treatment benefit | prevention only a weak trend |
| Valerian and other phytopharmaceuticals | sleep disorders | S3 insomnia 2025: “should not be recommended”, grade B | not shown objectively |
| Saw palmetto | prostate symptoms | Cochrane 2023: “little to no benefits”; EAU 2026: weak, hexane extract only | even a higher dose no better than placebo |
| Black cohosh (Cimicifuga) | hot flashes | S3 menopause 2020: “can … be used”, grade 0 | Cochrane 2012: “insufficient evidence” |
St John's wort for mild to moderate depression
Supported by meta-analyses and guidelines, with clear limitsFirst, three sentences that matter to me. Depression is a serious illness, not a passing low mood. St John's wort does not replace psychiatric or psychotherapeutic treatment and is no reason to postpone it. And anyone taking an antidepressant does not switch to St John's wort on their own, because the combination can become dangerous and stopping abruptly carries its own risks.
A Cochrane team around Linde pooled 29 double-blind trials with 5489 patients with major depression.
Compared with placebo, the ratio of response rates was 1.28 in nine larger trials and 1.87 in nine smaller ones. Compared with older antidepressants and SSRIs, it was 1.02 and 1.00, with fewer dropouts due to side effects, and trials from German-speaking countries were more favorable to St John's wort.
What this means for you: the extracts tested did better than placebo and similarly to standard antidepressants. But large trials showed smaller effects than small ones, and the country of origin played a part.
Linde K, Berner MM, Kriston L. Cochrane Database Syst Rev. 2008. PMID: 18843608 [Systematic Review, Cochrane]A systematic review around Apaydin with 35 studies confirmed, with moderate quality of evidence, more response than with placebo, but stressed the lack of research on severe depression and that rare harms were not captured (Apaydin 2016). A meta-analysis around Ng pointed out that all comparative trials with SSRIs lasted only 4 to 12 weeks and that it remains unclear whether people with severe depression or high suicidality benefit (Ng 2017).
An open “can” recommendation, tied to conditions
German NVL Unipolar Depression, version 3.2: “If drug therapy is being considered for mild depressive episodes, a first treatment attempt with a St John's wort preparation authorized as a medicinal product can be offered after information about specific side effects and interactions.” For moderate episodes, the same open recommendation applies to a preparation authorized “for this indication”. The guideline group gives this open recommendation explicitly for patients who prefer such a preparation, and it justifies the restriction to authorized preparations with their better standardization of dosing.
WFSBP and CANMAT, 2022: St John's wort receives the highest rating “+++” for unipolar depression, saffron “++”. The taskforce, however, recommends such remedies primarily as an add-on within standard medical or therapeutic care, especially in more severe illness.
What this means to me: a serious option for mild to moderate depression, under medical supervision, with an authorized preparation and a checked medication list. Not a self-experiment and not a substitute for psychotherapy or psychiatric treatment.
What the saffron studies show is covered in Saffron for low mood, and how I look at depression as a whole in Depression seen as a whole.
Peppermint oil for irritable bowel syndrome
Supported by meta-analyses and a guideline with an important counter-studyIf you have irritable bowel syndrome, you know the feeling that your gut has its own weather. Before irritable bowel syndrome is even considered, other causes need to be ruled out by a doctor, and red flags such as blood in the stool, unintended weight loss, fever or symptoms at night need prompt assessment. After that, of all the herbal remedies in this article, peppermint oil has the strongest recommendation in a German guideline.
The German S3 guideline on irritable bowel syndrome, 2021 version, states: “Peppermint oil has proven effective for treating mainly the IBS symptoms ‘pain’ and ‘bloating’ and shall be considered.” Recommendation grade A, strong consensus. Enteric-coated capsules could be used effectively in the short term; data on long-term use were lacking. The basis includes a meta-analysis around Khanna with nine trials and 726 patients: peppermint oil was superior to placebo for global improvement with a relative risk of 2.23 and for abdominal pain with 2.14; side effects were mild, most commonly heartburn (Khanna 2014).
A large trial using FDA and EMA endpoints missed its primary endpoint
A group around Weerts tested, double-blind over eight weeks in 190 patients, two peppermint oil capsules releasing in the small intestine or at the transition to the colon against placebo. For abdominal pain response there was no significant difference: 29 of 62 in the small-intestine group (46.8 percent), 26 of 63 in the colon group (41.3 percent), 22 of 64 on placebo (34.4 percent). The small-intestine version did, however, improve secondary endpoints such as abdominal pain, discomfort and severity more than placebo, with more frequent mild side effects.
A later meta-analysis around Ingrosso with ten trials and 1030 patients still found peppermint oil superior, with a number needed to treat of 4 and a confidence interval of 2.5 to 71, but rated the quality of evidence as “very low”. An overview from 2026 calculated a relative risk of 1.63 for peppermint oil from seven trials and found too few data for most other plant substances (Meyer 2026).
The guideline says “shall be considered”, not “shall be given”. And irritable bowel syndrome has more than one lever, as I describe in Irritable bowel syndrome: finding causes, Applying FODMAP correctly and gut-directed hypnotherapy.
A lavender oil extract for anxiety
Positive studies, manufacturer-funded, rated differently in guidelinesAnxiety can take over the whole body. Anxiety disorders are serious illnesses and belong in specialist medical and psychotherapeutic treatment. Lavender shows how differently experts can read the same data.
A group around Kasper, which according to PubMed included two employees of the manufacturer, treated 539 adults with generalized anxiety disorder for ten weeks with the extract at two daily doses, with paroxetine or with placebo.
The anxiety score fell by 14.1 and 12.8 points on the two extract doses, by 11.3 points on paroxetine and by 9.5 points on placebo. Both extract doses were superior to placebo; paroxetine showed only a trend.
What this means for you: the result speaks for the extract. But because the established comparator drug also did not clearly separate from placebo, it is hard to say how sensitive the trial was to differences.
Kasper S et al. Int J Neuropsychopharmacol. 2014;17(6):859-69. PMID: 24456909 [RCT, n = 539]A meta-analysis around Dold, financially supported by the manufacturer, pooled all five placebo-controlled trials with 1213 adults, including people with subthreshold anxiety, generalized anxiety disorder and mixed anxiety and depression. The extract was superior to placebo, the ratio of responder rates was 1.34, and there was no significant difference in side effects (Dold 2023). That does not make the result wrong, but independent replications are missing.
No recommendation in Germany, “++” internationally
German S3 guideline on anxiety disorders, version 2, 2021: Although evidence level 1b is reached because of a placebo-controlled trial, in the view of the guideline group the data do not permit a recommendation for the treatment of generalized anxiety disorder. Long-term studies are lacking. According to the guideline, the extract is not authorized for anxiety disorders according to ICD-10, but for “states of restlessness with anxious mood”. The guideline considers an earlier comparison with the benzodiazepine lorazepam (Woelk 2010) too small, and notes that lorazepam was given only once instead of three times a day.
WFSBP and CANMAT, 2022: Lavender and ashwagandha are rated “++” as modestly supported for anxiety disorders, while kava for generalized anxiety is explicitly not recommended with “(-)”. More on ashwagandha in Ashwagandha: who it may make sense for.
A ginkgo extract for dementia
Supported, but weak and narrowly definedHardly any plant is so automatically linked with “good for memory” as ginkgo. Here, treatment and prevention tell two different stories.
In 2008, the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed ginkgo-containing preparations against placebo in Alzheimer's dementia.
For activities of daily living it saw “proof of a benefit” for a specific extract at the high dose of 240 mg daily, and for cognition and psychopathological symptoms an “indication”. The results were very heterogeneous, strongly influenced by two studies from an Eastern European care setting, the benefit possibly existed only with accompanying psychopathological symptoms, and there was proof of more study dropouts due to adverse events than on placebo.
What this means for you: more positive than many think, but valid for one extract, one dose and one specific group.
IQWiG. Final report A05-19B, 2008. [Regulatory document, IQWiG]The German S3 guideline on dementia, 2023 version, puts it weakly: “We suggest” using a ginkgo extract named in the guideline “at a dose of 240 mg daily to treat cognition and everyday functioning in mild to moderate Alzheimer's dementia or vascular dementia with non-psychotic behavioral symptoms”. The dose is a guideline statement, not a recommendation from me. The 2026 Cochrane review around Wieland with 82 studies sees possibly small to moderate benefits in dementia after six months, with low certainty and very high heterogeneity. In mild cognitive impairment, ginkgo probably has little or no effect.
Two large prevention trials without benefit
In the GEM trial around DeKosky, 3069 people aged 75 and over received ginkgo extract or placebo, for a median of 6.1 years. 523 developed dementia, 246 on placebo and 277 on ginkgo, with no significant difference. In the manufacturer-funded GuidAge trial around Vellas with 2854 people aged 70 and over with memory complaints, probable Alzheimer's dementia was diagnosed over five years in 61 participants on ginkgo (1.2 cases per 100 person-years) and 73 on placebo (1.4 per 100 person-years), again with no significant difference.
What this means for you: these two large trials provide no basis for preventing dementia. That is a different question from treating diagnosed dementia.
Even the best herbal preparations have a narrow indication. That is not a flaw. That is medicine. An antibiotic is not “good for your defenses” either, but for specific pathogens in specific infections.
And now you know why “herbal and proven” almost never applies to a whole plant, but to one preparation, one diagnosis and one group of people.
Mixed or negative: pelargonium, echinacea, valerian, saw palmetto, black cohosh
“And what about the classics for colds, sleep problems and menopause?” These are exactly the remedies found in many households. And it is precisely for them that the study situation is often more sobering than the advertising sounds.
Colds and cough: pelargonium and echinacea
Mixed, low quality of evidenceA Cochrane team around Timmer evaluated studies on a root extract of the South African geranium (Pelargonium sidoides) in acute respiratory tract infections.
In acute bronchitis in adults, three studies with 746 patients showed effects with the liquid preparation, not with tablets, at low quality of evidence. For colds and sinusitis, the authors see possible efficacy, but “doubt exists”, at very low quality of evidence and with suspected publication bias.
What this means for you: signals on shaky foundations, valid for only one dosage form.
Timmer A et al. Cochrane Database Syst Rev. 2013. PMID: 24146345 [Systematic Review, Cochrane]The German general practice guideline from DEGAM on cough, version 3.2, describes mostly positive results for individual phytotherapeutics, “which, however, are of questionable clinical relevance”, and considers certain phytopharmaceuticals “worth considering” when the patient wishes treatment. On pelargonium, it notes that a warning about possible liver injury has been in the product information since 2014, that the benefit-harm ratio “cannot currently be conclusively” assessed, and that an increase in the blood-thinning effect of vitamin K antagonists cannot be ruled out.
For echinacea, the picture is more reserved. A Cochrane review around Karsch-Völk with 24 double-blind trials found no significant difference in any of the twelve prevention comparisons, and of seven treatment trials on the duration of colds, only one showed a significant effect. Conclusion: no demonstrated benefit for treatment; for prevention, possibly a weak benefit of individual products of questionable clinical relevance.
Sleep: valerian and other phytopharmaceuticals
Guideline negative, methodological dispute openThe German S3 guideline on insomnia, 2025 update, states: “Treatment of insomnia with phytopharmaceuticals should not be recommended”, recommendation grade B, and an umbrella review found no proof of efficacy for valerian in insomnia, at most signs of subjectively better sleep quality without confirmation by objective measurements (Valente 2024). How phytotherapy experts criticize this assessment is described further below, and you will find more in Valerian and passionflower, a study check and herbal sleep aids put into context. If you take sleeping pills: the note on stopping from the box at the beginning applies here just the same.
Prostate: saw palmetto
Negative, with high certaintyThe Cochrane review around Franco with 27 studies and 4656 participants concludes with high certainty that saw palmetto alone provides little or no benefit for symptoms caused by benign prostatic enlargement, after three to six months as well as after 12 to 17 months. Ten studies were industry-funded.
In the CAMUS trial around Barry, 369 men received a saw palmetto extract over 72 weeks at increasing doses up to three times the standard amount, or placebo. The symptom score fell from 14.42 to 12.22 points on the extract and from 14.69 to 11.70 points on placebo, and the extract was not better on any secondary endpoint. What this means for you: with subjective symptoms, it is hard to say what a remedy contributes without a placebo group.
Barry MJ et al. JAMA. 2011;306(12):1344-51. PMID: 21954478 [RCT, n = 369]Prostate symptoms belong in urological assessment, immediately if there is blood in the urine or you can no longer pass urine, and an existing treatment is not swapped for a herbal preparation on your own.
Menopause: black cohosh
Guideline open, Cochrane skepticalThe German S3 guideline on peri- and postmenopause, 2020 version: “Cognitive behavioral therapy (CBT), isoflavones and Cimicifuga preparations can be used for vasomotor symptoms.” Recommendation grade 0, together with the note in the background text to inform women that there are many preparations with unclear safety and that interactions have been reported. A Cochrane review around Leach with 16 studies and 2027 women found no significant difference from placebo in the frequency of hot flashes, which could be analyzed in three studies with 393 women, and saw “insufficient evidence”. The not yet adopted draft of the 2026 revision keeps a weak “can” recommendation with low to very low certainty and states for mood swings and depression that Cimicifuga “should not be recommended because of the limited evidence”, grade B. More in Menopause put into context and Chasteberry put into context.
Incidentally, the same S3 guideline that strongly recommends peppermint oil for irritable bowel syndrome also reports negative findings: turmeric with no significant difference from placebo, ginger alone without positive effects, St John's wort without a positive effect and, in diarrhea, even worse than placebo. Where turmeric can be interesting is covered in Turmeric and inflammation.
A no from a good study is knowledge too. It saves you money and hope in the wrong place.
And now you know why “herbal” is not a class of effect: the same plant can be well studied for one complaint and perform worse than placebo for another.
Herbal does not mean harmless: interactions, pregnancy, liver
“What could be dangerous about tea and tablets made from plants?” Herbal remedies often go unmentioned in conversations with doctors, probably because many people do not consider them medicines. That is exactly where a risk can arise.
Observation, not a study result
When I ask about medicines in my consultations, tablets are usually listed completely. Teas, drops and capsules from the drugstore, on the other hand, are often missing until I ask explicitly. That is why I ask about them specifically every time.
St John's wort as an enzyme accelerator
- Constituents, above all hyperforin, can activate the pregnane X receptor, PXR for short, a kind of switch for the cell's detoxification program.
- As a result, more breakdown enzymes can be produced, above all CYP3A4, and according to the EU monograph also CYP2B6, CYP2C9 and CYP2C19, as well as more P-glycoprotein, a pump that moves active substances out of cells.
- Medicines that are broken down or transported via these routes can fall in the blood and have a weaker effect.
- After stopping, enzyme activity returns to baseline within one week according to the monograph, and levels can rise again.
Altered levels have been described for digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin and oral contraceptives, among others (Nicolussi 2020).
The EU monograph lists concomitant use of the extracts with well-established use and of traditional preparations with more than 1 mg hyperforin per day as contraindicated with, among others, coumarin-type anticoagulants, ciclosporin, everolimus, sirolimus and systemic tacrolimus, HIV protease inhibitors and nucleoside reverse transcriptase inhibitors, as well as irinotecan, imatinib and other cytostatics broken down via these routes. How serious this is was shown as early as 2000 by a report around Ruschitzka in the Lancet: in two people after heart transplantation who were taking ciclosporin and St John's wort, acute rejection occurred, which the authors attributed to a metabolic interaction. Two cases are not statistics, but they are a clear warning sign.
The pill, antidepressants, anticoagulants and operations
The pill. In a study around Hall, 7 of 12 women had breakthrough bleeding during the St John's wort phase, compared with 2 of 12 in the control phase (Hall 2003). In a second study around Murphy with 16 women, hormone exposure from the pill fell by 13 to 15 percent, with signs of follicle growth and probable ovulation (Murphy 2005). A systematic review of four studies saw this as a reason for concern about contraceptive reliability (Berry-Bibee 2016), and the monograph recommends additional contraceptive measures. Please do not stop the pill or a prescribed medicine on your own; discuss the combination with your doctor or pharmacist.
Antidepressants. According to the monograph, St John's wort together with serotonin reuptake inhibitors or buspirone can contribute to serotonergic effects, very rarely up to serotonin syndrome. Such a combination never belongs in self-management.
Anticoagulants. With vitamin K antagonists, the window is narrow: deviations can lead to bleeding or thrombosis, and herbs and over-the-counter remedies can shift the benefit-risk balance (Di Minno 2017). For standardized ginkgo extract, a meta-analysis of 18 studies found no abnormal coagulation values (Kellermann 2011). However, laboratory values were measured, not bleeding events, and not specifically in people taking anticoagulants. The combination should therefore still be discussed with a doctor.
Operations. A review in JAMA named echinacea, ephedra, garlic, ginkgo, ginseng, kava, St John's wort and valerian as remedies that can cause problems around an operation, from a tendency to bleed to an increase in the sedative effect of anesthetics, and called for herbal remedies to be asked about explicitly before every operation (Ang-Lee 2001). So mention them before every planned procedure, even if nobody asks.
Pregnancy and breastfeeding. For St John's wort, the monograph states: “Safety during pregnancy and breast-feeding has not been established.” It adds that animal studies have shown signs of reproductive toxicity and states: “The use is not recommended during pregnancy and lactation.” Use during pregnancy and breastfeeding is therefore explicitly not recommended. If you are already taking St John's wort and are pregnant or breastfeeding, please discuss the next steps promptly with a doctor rather than deciding alone. Any use of herbal remedies during this time should be discussed with a doctor.
The liver: rare, but real
The liver processes almost everything we swallow. With herbal remedies it is worth taking a close look, without panic and without playing things down.
The European Food Safety Authority assessed the safety of green tea catechins, above all EGCG. According to this assessment, green tea as a traditionally prepared beverage is generally considered safe, and rare liver injuries are probably due to individual hypersensitivity. In intervention studies, however, amounts from 800 mg EGCG per day taken as a food supplement led to a significant increase in liver values.
What this means for you: the step from the beverage to the concentrated capsule can change the risk. A review by the US Pharmacopeia found case reports from as little as 140 mg EGCG per day, with large individual differences and, according to animal and human data, higher absorption on an empty stomach (Oketch-Rabah 2020). These are risk thresholds, not intake recommendations.
EFSA ANS Panel. EFSA J. 2018;16(4):e05239. PMID: 32625874 [Regulatory document, EFSA]Kava is potentially hepatotoxic according to a clinical review around Teschke, based among other things on a positive rechallenge test, with overdose, long-term use and concomitant medication as risk factors (Teschke 2010). In Germany, kava is prescription-only.
In the Berlin Case-Control Surveillance Study around Douros, liver injuries from Berlin hospitals were recorded over just over nine years and examined for their cause. In 10 of 198 cases a herbal cause was classified as probable or possible, among them, as possible, valerian five times and peppermint, pelargonium, St John's wort and eucalyptus once each. Acute liver failure or deaths did not occur.
What this means for you: rare events, and according to the authors a possible causality does not yet establish clinical significance. But even plants with a harmless reputation belong in the conversation when liver values rise.
Douros A et al. Int J Mol Sci. 2016;17(1):114. PMID: 26784183 [Real-World, n = 198]For pelargonium the link is disputed: an analysis around Teschke found no case with highly probable or probable causality among 15 spontaneous reports (Teschke 2012), and other experts disagreed in a letter to the editor. In the US Drug-Induced Liver Injury Network, the share of cases due to herbal remedies and dietary supplements rose from 7 to 20 percent over the study period. The reference is all liver injuries recorded in the network, not all people who take such products (Navarro 2014).
What the studies on milk thistle show is covered in Milk thistle and the liver. What matters for the liver in everyday life I describe in what matters for the liver.
What you can do in practical terms
- Write everything on your medication list, including teas, drops and capsules, and show it at your practice and pharmacy.
- Have interactions checked before you start a herbal preparation, especially if you take anticoagulants, immunosuppressants, HIV or cancer medicines, antidepressants or hormonal contraception.
- Report new symptoms such as dark urine, yellowing, bruising or breakthrough bleeding instead of waiting them out.
- Name all herbal remedies before every planned operation. Whether anything is paused is decided by the treatment team.
What can have an effect can also have side effects. The question is never “herbal or chemical”, but “which substance, in what amount, together with what”.
And now you know why the friendly green box belongs on your medication list.
Quality: adulteration, heavy metals, pyrrolizidine alkaloids
“How do I know that what is on the label is inside?” The following findings mainly concern food supplements, imports and products bought online, not the medicines authorized or registered in Germany. Still, they belong in an honest assessment.
Adulteration. An analysis around Ichim collected DNA-based authentication tests of 5957 commercial herbal products from 37 countries. According to this analysis, 27 percent were adulterated, meaning they contained undeclared admixtures, substitute plants, fillers or not the stated plant at all (Ichim 2019). The data mix product categories and countries and cannot be transferred to German pharmacy products.
A team around Nortier examined people who had taken slimming pills containing Chinese herbs. Due to a manufacturing error, one plant had been replaced by Aristolochia fangchi, which according to the authors is nephrotoxic and carcinogenic. In 39 patients with end-stage kidney failure who agreed to preventive surgery, 18 urothelial carcinomas were found, and the total amount ingested was a significant risk factor.
What this means for you: a plant mix-up is not a cosmetic error, and the danger then lies in a plant that is not named on any pack.
Nortier JL et al. N Engl J Med. 2000;342(23):1686-92. PMID: 10841870 [Case Series, 39 operated patients]Heavy metals. A group around Saper analyzed 193 Ayurvedic preparations ordered online. 20.7 percent contained lead, mercury or arsenic, 75 percent of the contaminated products advertised good manufacturing practice, and all contaminated products exceeded at least one standard for tolerable daily intake (Saper 2008). A quality promise on a website is therefore not a test result. More in Heavy metals in the body and Lead exposure: symptoms and sources.
Pyrrolizidine alkaloids are plant toxins found in many plant species that are suspected of being genotoxic and carcinogenic. In a European market survey around Mulder with 1105 samples from 2014 and 2015, at least one of them was found in 91 percent of teas and herbal teas and in 60 percent of food supplements (Mulder 2018). In 2017, the European Food Safety Authority saw a possible concern mainly for people who frequently drink large amounts of tea and herbal tea, and, for food supplements made from plants that produce such substances, a possible intake that could be too close to doses with severe acute toxicity. I deliberately do not convert this into cups, and I have not separately checked the current level of contamination.
What you can look out for
Authorized and registered herbal medicines go through an official procedure, whereas food supplements are not checked by any authority before sale. That is not a verdict on individual products, but a difference in safeguards.
- Look at the number. Zul.-Nr. or Reg.-Nr. show that a medicinal product procedure has taken place.
- Prefer traceable sources such as a pharmacy over unclear imports from the internet.
- Look for a precise description of the preparation. If the type of extract and the solvent are missing, the basis for matching it to studies is missing.
I deliberately do not recommend quality seals or brands. What to make of detox programs and detox teas is covered in Detox programs, a critical look.
Natural is a word of origin, not a seal of approval. Arsenic, lead and Aristolochia are natural too.
Why there are fewer large studies, and how guidelines include phytotherapy
“If plants have been used for centuries, why is so little known?” There are reasons that can be documented, and one that is often cited but that I could not substantiate in my research.
First: legally it is often not necessary. Traditional medicines are registered without clinical trials, an authorization can be granted on a bibliographic basis, and Commission E assessed mainly on a bibliographic basis. Anyone allowed to sell on these terms has, at least legally, little reason for an expensive study.
Second: every study applies to only one extract. Anyone who pools ten valerian studies with ten preparations is mixing unlike things. The DEGAM guideline calls such meta-analyses “methodologically difficult”, and the S3 guideline on irritable bowel syndrome considers pooling “not meaningful”. An early valerian meta-analysis of 16 studies described considerable methodological problems, very different preparations and signs of publication bias (Bent 2006).
Third: many studies do not report what exactly was tested. 406 randomized trials of herbal remedies reported on average only 38 percent of the items recommended in a checklist (Gagnier 2011), even though the CONSORT reporting standard had been extended for herbal trials back in 2006, with the most extensive addition, of all places, in the description of the intervention (Gagnier 2006).
Fourth: large studies often come from manufacturers. This applies to the large lavender trial and the lavender meta-analysis, to ten studies in the Cochrane review on saw palmetto and to the meta-analysis on the hexane extract. That is not proof of a wrong result: the manufacturer-funded GuidAge trial on ginkgo was negative and was published. It only means that independent replications are especially valuable.
Plausible consideration, not substantiated in this research
You often read that plants are hard to patent, and that this is why money for large studies is lacking. That sounds plausible. But I did not find a study that shows this connection. That is why I present it as a consideration, not as a fact.
How guidelines assess phytotherapy
A systematic overview around Klose screened 128 German S3 guidelines. Phytotherapy appeared in 40 of them. Of 204 recommendations, 139, or 68.1 percent, were negative or open, side effects and interactions were mentioned in 70 of the 204 recommendations, and fewer than half of the guidelines included phytotherapy in their literature search at all (Klose 2014). When reading, pay attention to the small words: in German guidelines “soll” (shall), “sollte” (should) and “kann” (can) are fixed grades of strength.
| Guideline, version | Remedy | Wording | Strength |
|---|---|---|---|
| NVL Depression 3.2 | authorized St John's wort preparations | “can … be offered” (kann … angeboten werden) | open |
| S3 IBS 2021 | peppermint oil | “shall be considered” (soll erwogen werden) | grade A |
| S3 IBS 2021 | other phytotherapeutics | “should be integrated individually into the treatment concept” (sollten individuell ins Behandlungskonzept integriert werden) | grade B |
| S3 anxiety 2021 | a lavender oil extract | “no recommendation” (keine Empfehlung) for generalized anxiety disorder | none |
| S3 dementia 2023 | a ginkgo extract | “We suggest” (Wir schlagen vor) | weak |
| S3 insomnia 2025 | phytopharmaceuticals | “should not be recommended” (sollte nicht empfohlen werden) | grade B |
| DEGAM cough 3.2 | certain phytopharmaceuticals | “worth considering” (zu erwägen) when the patient wishes treatment | consideration |
| S3 menopause 2020 | black cohosh, isoflavones | “can … be used” (können … angewendet werden) | grade 0 |
| EAU LUTS 2026 | hexane extract of saw palmetto | “Offer”; “Inform … modest” | “Weak”, “Strong” |
The methodological dispute, presented fairly
The view from phytotherapy: In a critical appraisal of the S3 guideline on insomnia, Kraft, Kelber and Köhler write that meta-analyses of herbal studies are, because of the high heterogeneity of the preparations, “mostly hardly suitable as a basis” for guideline recommendations, and that systematic reviews and individual randomized trials are better. The argument deserves to be taken seriously, because it is exactly the problem of non-interchangeable extracts.
This is how the restraint of the guideline groups can be read: recommendations need robust, replicated studies. Where the data consist of small or heterogeneous studies, they remain cautious, and that can protect against hopes that are later not confirmed.
To me, both are true. Heterogeneity is a genuine methodological problem and at the same time not evidence of efficacy. The solution would be good studies on precisely defined preparations.
An image for it: guidelines are like a mountain guide who only recommends paths he has walked several times himself. That does not mean there are no other paths. He just does not vouch for them.
No recommendation does not always mean “ineffective”. Often it means: not studied well enough. And conversely, a long tradition does not mean that something is well studied.
Reading the evidence yourself: five questions for every pack and every study
“How am I supposed to tell the difference in everyday life?” You do not need any knowledge of statistics, just a handful of questions you can ask yourself, your pharmacy or your practice.
Five questions that almost always move you forward
- What status does the product have? Zul.-Nr., Reg.-Nr. with a note on long-standing use, or a food supplement without a medicinal product number.
- Which preparation exactly? Type of extract, extraction solvent, drug extract ratio. And: was exactly this preparation studied, or only “the plant”?
- How large and how good was the study? Placebo and blinding, number of participants, duration, objective or subjective endpoints, and was the primary endpoint met? The saw palmetto trial with clear improvement on placebo and the peppermint oil trial with a missed primary endpoint show why this matters.
- Who paid, and are there independent replications? Manufacturer funding is not an exclusion criterion, but a result from only one source stands on one leg.
- What do Cochrane, IQWiG and the guideline say word for word, and does the remedy fit with your medicines? Pay attention to “shall”, “should” and “can”, to the group named and the version, and have interactions checked.
You can also remember two warning signals. When small studies show clearly better results than large ones, as with St John's wort at 1.87 compared with 1.28, caution about the effect size is warranted. And when a review suspects publication bias, as with pelargonium, unfavorable studies could be missing from the analysis.
Four levels on which a statement can stand
- Supported by large RCTs and meta-analyses
Certain St John's wort extracts for mild to moderate depression and peppermint oil in the short term for irritable bowel syndrome, each with limits. Equally well supported, but negative: saw palmetto for prostate symptoms and ginkgo for preventing dementia. - Mechanistically plausible, human studies thin
The assumption that low-hyperforin St John's wort preparations cause hardly any interactions: the mechanism fits, but the human data come from one study with 20 healthy men over two weeks. - Clinical tradition without a strong study base
Traditionally registered medicines: long use, plausible efficacy, no clinical trial required. An honest category, but not a study finding. - What I observe clinically
That herbal remedies are often missing from medication lists until you ask specifically. Experience from my consultations, not a study result.
I like to use herbal medicines as one building block when diagnosis, preparation, evidence and medication list fit together: first a thorough assessment, then the question of a well-studied preparation for exactly this situation, then the interaction check. For me, phytotherapy is not a substitute for necessary treatment and not a reason to change ongoing therapy. And it matters to me that you can recognize for yourself whether a pack stands for a tested benefit, a long tradition or a food.
Where to go next in the Medicinal Plants category
This page puts things into context and points onward. What the term adaptogens means is covered in Adaptogens: what the term means. What is known about frankincense I put into context in Frankincense for joints and gut. Intravenous administration of plant substances is a separate topic, described in Medicinal plants by infusion. How plant substances and the microbiome might interact is covered in Medicinal plants and the microbiome, and herbal remedies for small intestinal bacterial overgrowth I put into context in Oregano oil and berberine in SIBO.
You do not need to be able to read studies. You only need to know which questions to ask: which preparation, which status, which study, who paid, what does the guideline say, and does it fit with what else I take.
And now you know why the best question before any herbal remedy is not “Is it natural?”, but “What exactly is this, and what is known about it?”.
Frequently asked questions about phytotherapy and herbal medicines
What is phytotherapy, in simple terms?
Phytotherapy is treatment with herbal medicinal products, meaning medicines whose active ingredients, according to the German Medicines Act, are exclusively herbal substances or preparations, such as extracts, tinctures or oily macerates. The term rational phytotherapy is used when these medicines are measured against the same scientific standards as other medicines. The depth of data varies widely. Herbal therefore describes where a medicine comes from, not how effective or how safe it is.
What is the difference between phytotherapy and homeopathy?
Phytotherapy works with plant preparations whose constituents can be measured, usually as an extract in a defined amount. In Germany, homeopathic medicinal products can be registered without submitting information on effects and indications (§ 38 (2) AMG). Anthroposophic medicinal products are developed according to the anthroposophic understanding of the human being and nature (§ 4 (33) AMG). The German Medicines Act provides a separate approval commission for each of these three therapeutic approaches.
What does “traditional herbal medicinal product” mean on the pack?
It was registered on the basis of long-standing use, not efficacy studies: at least 30 years of medicinal use, 15 of them in the EU, not harmful under the stated conditions of use, and with efficacy that is plausible on the basis of long-standing experience (§ 39b AMG). According to the European Medicines Agency, clinical trials are not required. In Germany the pack carries a registration number (Reg.-Nr.) and the mandatory statement that the product is registered exclusively on the basis of long-standing use. That is honest labeling, but not proof of efficacy.
Which herbal medicines are well studied? A few examples
The best studied are a few precisely defined preparations with a narrow indication: certain authorized St John's wort extracts for mild to moderate depression (guideline: “can” be offered), peppermint oil in enteric-coated capsules for irritable bowel syndrome (guideline: “shall be considered”), a specific lavender oil extract for anxiety (positive, manufacturer-funded studies, but no recommendation in the German S3 guideline) and a standardized ginkgo extract for mild to moderate Alzheimer's or vascular dementia with non-psychotic behavioral symptoms (weak recommendation). Each statement applies only to the preparation studied and the group studied.
Is phytotherapy scientifically proven?
There is no blanket answer, because phytotherapy is not a single remedy. For individual extracts there are meta-analyses and guideline recommendations, for example for St John's wort or peppermint oil. For many popular remedies the evidence is mixed or negative, for example for saw palmetto or echinacea. In an analysis of 128 German S3 guidelines, 68.1 percent of the 204 recommendations on phytotherapy were negative or open. In short: yes for a few preparations, no or only weakly for many.
Are herbal remedies safer than synthetic drugs?
Not automatically. St John's wort can speed up the breakdown of many medicines and, according to the EU monograph, is contraindicated with, among others, coumarin-type anticoagulants, certain immunosuppressants and HIV medicines. Green tea extract, kava and, in isolated cases, valerian have been linked to liver injury, and imports bought online add the problem of contamination. Many herbal preparations are well tolerated in studies, but that is no free pass for every combination. That is why they belong on every medication list.
Can St John's wort replace an antidepressant?
This article does not advise replacing an antidepressant with St John's wort. The German National Disease Management Guideline (NVL) sees an authorized St John's wort preparation as an open “can” option for a first treatment attempt in a mild or moderate episode, when drug treatment is being considered, and only after the patient has been informed. Data are lacking for severe depression, and St John's wort does not replace psychotherapy. An antidepressant is not stopped abruptly or switched on your own, because that carries its own risks and St John's wort in combination can contribute to serotonergic effects. Any change belongs in the hands of the prescribing doctor. If you have suicidal thoughts: in Germany, the Telefonseelsorge crisis line 0800 111 0 111 or 0800 111 0 222, in acute danger 112. These are German numbers; outside Germany, please contact your local crisis line or emergency services.
Does St John's wort make the pill ineffective?
St John's wort can impair the reliability of hormonal contraception. In one study, 7 of 12 women had breakthrough bleeding during the St John's wort phase, compared with 2 of 12 in the control phase. In a second study with 16 women, hormone exposure fell by 13 to 15 percent, with signs of probable ovulation. The EU monograph recommends additional contraceptive measures. Do not stop the pill or a prescribed medicine on your own; discuss the combination with your doctor or pharmacist.
Does health insurance pay for herbal medicines?
In Germany, statutory health insurance may cover non-prescription medicines only by way of exception, when they are considered the standard of care for serious diseases; this restriction does not apply to children up to their 12th birthday or to adolescents with developmental disorders up to their 18th birthday. The exception list of the Federal Joint Committee (G-BA) names, among others, a standardized Ginkgo biloba leaf extract at a daily dose of 240 mg for this purpose, only for the treatment of dementia. Some herbal medicines require a prescription, for example St John's wort for the treatment of moderate depression, and kava-kava. Voluntary extra benefits offered by individual insurers are not a general rule, so it is worth asking your own insurer.
What do herbal remedies do for colds?
The German general practice guideline from DEGAM considers certain phytopharmaceuticals worth considering for moderate relief of acute cough when the patient wishes treatment, but calls the effects of questionable clinical relevance. For pelargonium there are signs of benefit in acute bronchitis, though with low quality of evidence, only for the liquid preparation and with a liver warning in the product information. For echinacea, a Cochrane review showed no proven benefit for treatment. Shortness of breath, high fever or persistent symptoms call for a medical assessment before any home remedy.
Are there herbal medicines for menopause?
The German S3 guideline on peri- and postmenopause from 2020 states that black cohosh (Cimicifuga) preparations, isoflavones and cognitive behavioral therapy can be used for hot flashes, recommendation grade 0, combined with information about differing preparations and interactions. A Cochrane review from 2012 found insufficient evidence for black cohosh. The not yet adopted draft of the 2026 revision keeps a weak “can” recommendation and advises against it for mood swings and depression. Which option fits belongs in a gynecological consultation.
How long were herbal medicines tested in studies?
Usually for a shorter time than many people take them. The St John's wort studies comparing it with SSRIs lasted 4 to 12 weeks, the lavender studies in the meta-analysis ten weeks, and for peppermint oil the guideline describes short-term use without long-term data. The current Cochrane review on ginkgo reports its main results after six months. These are study durations, not intake recommendations. How long a remedy makes sense can only be judged by a doctor for the individual case.
Can medicinal plants harm the liver?
Yes, rarely. For green tea extract as a food supplement, liver values rose significantly in studies from 800 mg EGCG per day, while green tea as a beverage is generally considered safe. Kava is considered potentially hepatotoxic. In a Berlin study, 10 of 198 cases of liver injury were classified as possibly or probably herb-induced, including valerian five times. Warning signs are yellowing of the skin or eyes, dark urine, pale stools, upper abdominal pain and unusual tiredness. In that case, please have it checked by a doctor promptly.
Continue reading from here
This pillar page points to individual articles in which single plants, organs and questions are discussed in detail. Twelve paths that lead on sensibly from here.
Curcumin and the question of absorption
Why dosage form and formulation can make such a difference with turmeric preparations.
If it is about inflammationTurmeric and inflammation
What curcumin shows in studies and where expectations run ahead of the data.
If your mood is lowSaffron for low mood
What the studies show and where their limits lie.
If you want to understand depression more broadlyDepression seen as a whole
A broad view of depression that thinks treatment and the search for causes together.
If sleep will not comeValerian and passionflower, a study check
What herbal calming can achieve in sleep disorders, checked against the studies.
If your gut runs your daily lifeIrritable bowel syndrome: looking for causes
Which causes can lie behind irritable bowel symptoms and what a structured search looks like.
If hot flashes and sleep are changingMenopause put into context
Symptoms, phases and the options available in this stage of life.
If it is about the liverMilk thistle and the liver
Detox myth or protection? What the studies show.
If you are standing in front of the supplement shelfWhen food supplements make sense
When a supplement can make sense and when it tends to get in the way.
If you come across the word adaptogenAdaptogens: what the term means
Where the term comes from, what it means and what it does not promise.
If plant substances are meant to go into a veinMedicinal plants by infusion
What the studies show on intravenous administration of plant substances.
If you are thinking about contamination from importsHeavy metals in the body
Lead, mercury and more: what can be in the body and how it is measured.
Scientific sources
68 sources, 50 of them with DOI. Guidelines, legal and regulatory sources without DOI are given with register number, version and status. Extract names appear only in original titles.
Guidelines
- Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Unipolare Depression, Langfassung, Version 3.2. AWMF register no. nvl-005. July 2023. [Guideline]
- Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, et al. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der DGVS und der DGNM. Z Gastroenterol. 2021;59(12):1323-1415. AWMF 021-016. PMID: 34891206 · DOI: 10.1055/a-1591-4794 [Guideline]
- Bandelow B, Aden I, Alpers GW, Benecke A, Benecke C, Deckert J, et al. Deutsche S3-Leitlinie Behandlung von Angststörungen, Version 2. AWMF register no. 051-028. As of 06.04.2021. [Guideline]
- Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN). S3-Leitlinie Demenzen. AWMF register no. 038-013. Version 1.0 of 29.11.2023; guideline report Living Guideline version 6.0, as of 24.02.2026. [Guideline]
- Spiegelhalder K, Baum E, Becker M, Cornaro C, Crönlein T, Frase L, et al. Leitlinie Insomnie bei Erwachsenen, Update 2025, Version 2.0. AWMF register no. 063-003. [Guideline]
- Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). S3-Leitlinie Akuter und chronischer Husten, DEGAM-Leitlinie Nr. 11, Version 3.2. AWMF register no. 053-013. As of 11/2025. [Guideline]
- DGGG, SGGG, OEGGG. S3-Leitlinie Peri- und Postmenopause, Diagnostik und Interventionen, Version 1.1. AWMF register no. 015-062. As of January 2020, incl. addendum September 2020. In addition, the consultation version of the revision “Peri- und Postmenopause: Diagnostik und Therapie”, draft June 2026, not adopted. [Guideline] [Guideline, draft 2026]
- Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23(6):424-455. PMID: 35311615 · DOI: 10.1080/15622975.2021.2013041 [Guideline] [Consensus Guideline, international taskforce]
- Cornu JN, Elterman D, Hashim H, Herrmann TRW, Karavitakis M, Malde S, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). European Association of Urology, Update March 2026. [Guideline]
Law and authorities
- Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz, AMG), § 4 (29) and (33), § 10 (4a), § 22 (3), § 25 (6) and (7), § 38 (2), § 39a to § 39c. gesetze-im-internet.de, accessed 16.09.2026. [Legal text]
- Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex CELEX 32004L0024. [Legal text]
- European Medicines Agency. Herbal medicinal products. ema.europa.eu, accessed 16.09.2026. [Regulatory document, EMA]
- Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Hypericum perforatum L., herba. Final, Revision 1. EMA/HMPC/7695/2021. Adopted on 23.11.2022. [Regulatory document, EMA/HMPC]
- Knöss W. Monographien als Richtschnur. Pharmazeutische Zeitung, issue 13/2014. [Overview, trade press]
- Institute for Quality and Efficiency in Health Care (IQWiG). Ginkgohaltige Präparate bei Alzheimer Demenz. Final report A05-19B, version 1.0, 29.09.2008. IQWiG reports 2008 no. 39. [Regulatory document, IQWiG]
- Verordnung über die Verschreibungspflicht von Arzneimitteln (Arzneimittelverschreibungsverordnung, AMVV), Anlage 1 (Annex 1). gesetze-im-internet.de, accessed 16.09.2026. [Legal text]
- Gemeinsamer Bundesausschuss (Federal Joint Committee, G-BA). Arzneimittel-Richtlinie, Anlage I: Zugelassene Ausnahmen zum gesetzlichen Verordnungsausschluss nach § 34 Abs. 1 Satz 2 SGB V (OTC-Übersicht). Reproduction as of May 2025, no. 20 in force since 09.06.2011. See also § 34(1) SGB V, gesetze-im-internet.de, accessed 17.09.2026. [Regulatory document, G-BA, secondary reproduction]
- Verordnung über Nahrungsergänzungsmittel (NemV), § 1 and § 5; Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (German Federal Office of Consumer Protection and Food Safety, BVL). Keine Zulassung von Nahrungsergänzungsmitteln notwendig. Press release of 27.01.2025. [Legal text] [Regulatory document, BVL]
- Court of Justice of the European Union. Judgment of 30 April 2025, Case C-386/23. EUR-Lex CELEX 62023CJ0386. [Legal text, judgment]
- EFSA Panel on Contaminants in the Food Chain (CONTAM), Knutsen HK, Alexander J, Barregård L, Bignami M, Brüschweiler B, et al. Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, herbal infusions and food supplements. EFSA J. 2017;15(7):e04908. PMID: 32625569 · DOI: 10.2903/j.efsa.2017.4908 [Regulatory document, EFSA]
- EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, et al. Scientific opinion on the safety of green tea catechins. EFSA J. 2018;16(4):e05239. PMID: 32625874 · DOI: 10.2903/j.efsa.2018.5239 [Regulatory document, EFSA]
Studies and reviews
- Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;2008(4):CD000448. PMID: 18843608 · DOI: 10.1002/14651858.CD000448.pub3 [Systematic Review, Cochrane, 29 RCTs, n = 5489]
- Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JN, Sorbero ME, Hempel S. A systematic review of St. John's wort for major depressive disorder. Syst Rev. 2016;5(1):148. PMID: 27589952 · DOI: 10.1186/s13643-016-0325-2 [Meta-analysis, 35 studies, n = 6993]
- Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. J Affect Disord. 2017;210:211-221. PMID: 28064110 · DOI: 10.1016/j.jad.2016.12.048 [Meta-analysis, 27 studies, n = 3808]
- Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE. Clinical relevance of St. John's wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212-1226. PMID: 31742659 · DOI: 10.1111/bph.14936 [Review]
- Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;355(9203):548-9. PMID: 10683008 · DOI: 10.1016/S0140-6736(99)05467-7 [Case Report, 2 cases]
- Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74(6):525-35. PMID: 14663455 · DOI: 10.1016/j.clpt.2003.08.009 [Human study, pharmacokinetics, n = 12]
- Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71(6):402-8. PMID: 15914127 · DOI: 10.1016/j.contraception.2004.11.004 [Human study, pharmacokinetics, n = 16]
- Berry-Bibee EN, Kim MJ, Tepper NK, Riley HE, Curtis KM. Co-administration of St. John's wort and hormonal contraceptives: a systematic review. Contraception. 2016;94(6):668-677. PMID: 27444983 · DOI: 10.1016/j.contraception.2016.07.010 [Systematic Review, 4 studies]
- Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, et al. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol. 2009;65(1):81-7. PMID: 18762932 · DOI: 10.1007/s00228-008-0554-y [Human study, pharmacokinetics, n = 20]
- Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505-12. PMID: 24100754 · DOI: 10.1097/MCG.0b013e3182a88357 [Meta-analysis, 9 RCTs, n = 726]
- Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, et al. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology. 2020;158(1):123-136. PMID: 31470006 · DOI: 10.1053/j.gastro.2019.08.026 [RCT, n = 190]
- Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56(6):932-941. PMID: 35942669 · DOI: 10.1111/apt.17179 [Meta-analysis, 10 RCTs, n = 1030]
- Meyer A, Auer J, Cascant-Ortolano L, Schreiber N, Zimmermann-Klemd A, Gründemann C, Busche P, Schirra J, Fox MR. Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome. Phytother Res. 2026. Epub ahead of print. PMID: 42572206 · DOI: 10.1002/ptr.70421 [Meta-analysis, 60 studies, n = 6329]
- Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A. Lavender oil preparation Silexan is effective in generalized anxiety disorder: a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859-69. PMID: 24456909 · DOI: 10.1017/S1461145714000017 [RCT, n = 539, manufacturer involvement]
- Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94-9. PMID: 19962288 · DOI: 10.1016/j.phymed.2009.10.006 [RCT, comparison with lorazepam]
- Dold M, Bartova L, Volz HP, Seifritz E, Möller HJ, Schläfke S, Kasper S. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1615-1628. PMID: 36717399 · DOI: 10.1007/s00406-022-01547-w [Meta-analysis, 5 RCTs, n = 1213, manufacturer-funded]
- Wieland LS, Ludeman E, Chi Y, Feinberg TM, Chen IH, Chen KH, Zhu Y, Wolverson E, Amri H. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2026;2(2):CD013661. PMID: 41641880 · DOI: 10.1002/14651858.CD013661.pub2 [Systematic Review, Cochrane, 82 studies, n = 10613]
- DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-62. PMID: 19017911 · DOI: 10.1001/jama.2008.683 [RCT, n = 3069]
- Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851-9. PMID: 22959217 · DOI: 10.1016/S1474-4422(12)70206-5 [RCT, n = 2854, manufacturer-funded]
- Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490-502. PMID: 21923430 · DOI: 10.1592/phco.31.5.490 [Meta-analysis, 18 RCTs, n = 1985]
- Kressmann S, Müller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol. 2002;54(5):661-9. PMID: 12005361 · DOI: 10.1211/0022357021778970 [Product analysis, US market]
- Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev. 2013;2013(10):CD006323. PMID: 24146345 · DOI: 10.1002/14651858.CD006323.pub3 [Systematic Review, Cochrane, 8 studies]
- Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2014;2014(2):CD000530. PMID: 24554461 · DOI: 10.1002/14651858.CD000530.pub3 [Systematic Review, Cochrane, 24 studies, n = 4631]
- Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol. 2012;63(1):1-9. PMID: 22381150 · DOI: 10.1016/j.yrtph.2012.02.009. Letter to the editor on this: Stammschulte T, Gundert-Remy U. Regul Toxicol Pharmacol. 2012;64(2):342. PMID: 22728685. [Case Series, 15 spontaneous reports]
- Douros A, Bronder E, Andersohn F, Klimpel A, Kreutz R, Garbe E, Bolbrinker J. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. Int J Mol Sci. 2016;17(1):114. PMID: 26784183 · DOI: 10.3390/ijms17010114 [Real-World, case-control surveillance, n = 198]
- Franco JV, Trivisonno L, Sgarbossa NJ, Alvez GA, Fieiras C, Escobar Liquitay CM, Jung JH. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6(6):CD001423. PMID: 37345871 · DOI: 10.1002/14651858.CD001423.pub4 [Systematic Review, Cochrane, 27 studies, n = 4656]
- Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-51. PMID: 21954478 · DOI: 10.1001/jama.2011.1364 [RCT, n = 369]
- Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-1065. PMID: 29694707 · DOI: 10.1111/bju.14362 [Meta-analysis, RCTs and observational studies, manufacturer involvement]
- Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005-12. PMID: 17145239 · DOI: 10.1016/j.amjmed.2006.02.026 [Meta-analysis, 16 studies, n = 1093]
- Valente V, Machado D, Jorge S, Drake CL, Marques DR. Does valerian work for insomnia? An umbrella review of the evidence. Eur Neuropsychopharmacol. 2024;82:6-28. PMID: 38359657 · DOI: 10.1016/j.euroneuro.2024.01.008 [Overview, umbrella review]
- Kraft K, Kelber O, Köhler S. Kritische Würdigung der S3-Leitlinie „Insomnie“. Z Phytother. 2025;46(05):234-243. DOI: 10.1055/a-2646-3426 [Commentary, specialist journal]
- Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;2012(9):CD007244. PMID: 22972105 · DOI: 10.1002/14651858.CD007244.pub2 [Systematic Review, Cochrane, 16 RCTs, n = 2027]
- Ichim MC. The DNA-Based Authentication of Commercial Herbal Products Reveals Their Globally Widespread Adulteration. Front Pharmacol. 2019;10:1227. PMID: 31708772 · DOI: 10.3389/fphar.2019.01227 [Systematic Review, 5957 products]
- Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thuppil V, Kales SN. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. 2008;300(8):915-23. PMID: 18728265 · DOI: 10.1001/jama.300.8.915 [Product analysis, n = 193]
- Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686-92. PMID: 10841870 · DOI: 10.1056/NEJM200006083422301 [Case Series, 39 operated patients]
- Mulder PPJ, López P, Castellari M, Bodi D, Ronczka S, Preiss-Weigert A, These A. Occurrence of pyrrolizidine alkaloids in animal- and plant-derived food: results of a survey across Europe. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018;35(1):118-133. PMID: 28942718 · DOI: 10.1080/19440049.2017.1382726 [Product analysis, n = 1105]
- Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399-408. PMID: 25043597 · DOI: 10.1002/hep.27317 [Cohort, prospective registry, n = 839]
- Oketch-Rabah HA, Roe AL, Rider CV, Bonkovsky HL, Giancaspro GI, Navarro V, et al. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicol Rep. 2020;7:386-402. PMID: 32140423 · DOI: 10.1016/j.toxrep.2020.02.008 [Systematic Review, USP]
- Teschke R. Kava hepatotoxicity: a clinical review. Ann Hepatol. 2010;9(3):251-65. PMID: 20720265 [Review]
- Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286(2):208-16. PMID: 11448284 · DOI: 10.1001/jama.286.2.208 [Review]
- Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017;31(4):193-203. PMID: 28196633 · DOI: 10.1016/j.blre.2017.02.001 [Review]
- Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364-7. PMID: 16520478 · DOI: 10.7326/0003-4819-144-5-200603070-00013 [Review, CONSORT reporting standard]
- Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Randomized controlled trials of herbal interventions underreport important details of the intervention. J Clin Epidemiol. 2011;64(7):760-9. PMID: 21208777 · DOI: 10.1016/j.jclinepi.2010.10.005 [Systematic Review, 406 RCTs]
- Heinrich M, Jalil B, Abdel-Tawab M, Echeverria J, Kulić Ž, McGaw LJ, Pezzuto JM, Potterat O, Wang JB. Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research: The ConPhyMP-Guidelines. Front Pharmacol. 2022;13:953205. PMID: 36176427 · DOI: 10.3389/fphar.2022.953205 [Review, consensus]
- Monagas M, Brendler T, Brinckmann J, Dentali S, Gafner S, Giancaspro G, et al. Understanding plant to extract ratios in botanical extracts. Front Pharmacol. 2022;13:981978. PMID: 36249773 · DOI: 10.3389/fphar.2022.981978 [Review]
- Klose P, Kraft K, Cramer H, Lauche R, Dobos G, Langhorst J. Phytotherapy in the German Medical AWMF S3 guidelines: a systematic overview. Forsch Komplementmed. 2014;21(6):388-400. PMID: 25592950 · DOI: 10.1159/000370079 [Systematic Review, 128 S3 guidelines]
- Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany. J Ethnopharmacol. 1991;32(1-3):225-9. PMID: 1881161 · DOI: 10.1016/0378-8741(91)90122-t [Review]
- Manufacturer funding. The data on the lavender oil extract are largely manufacturer-funded or involve the manufacturer, as do the meta-analysis on the hexane extract of saw palmetto and the GuidAge trial. Three of the four authors of the interaction review around Nicolussi worked, according to PubMed, for a Swiss manufacturer of herbal medicines. I did not check the conflicts of interest of the commentary from the Zeitschrift für Phytotherapie. Manufacturer funding is not evidence of a wrong result, but it is a reason to look for independent replications.
- The hyperforin threshold for clinically less relevant interactions rests on thin human data. No sentence in this article presents low-hyperforin preparations as free of interactions.
- Liver injury from pelargonium, valerian, peppermint or St John's wort is based on individual cases with possible causality and disputed spontaneous reports. The frequency is unknown.
- Ginkgo and bleeding risk: the meta-analysis measured coagulation values, not bleeding events. The review on preparing for surgery dates from 2001.
- The adulteration rate of 27 percent comes from a worldwide analysis of mixed product categories and does not apply to medicines authorized in Germany. A widely cited older DNA barcoding study was retracted in 2024 and is deliberately not cited. The data on pyrrolizidine alkaloids date from 2014 and 2015.
- Guideline status. According to the AWMF register, the S3 guideline on irritable bowel syndrome was valid until 30.03.2026; whether it has been extended could not be retrieved. The revision of the S3 guideline on peri- and postmenopause was only available as a draft that has not been adopted. The wording of the ginkgo recommendation comes from the 2023 version of the dementia guideline. I read the exception list of the Federal Joint Committee via a secondary reproduction; for ginkgo in dementia, the S3 guideline confirms reimbursement.
- The patent argument is marked as a consideration; no evidence was found. The 2026 peppermint oil meta-analysis had only been published online ahead of print, and I do not cite one internally inconsistent single value in the 2026 ginkgo Cochrane review.
- What is deliberately not included here. No product, brand or seal recommendation, no dosage recommendation, no intake schedule. The 240 mg for ginkgo is a guideline and reimbursement figure, the EGCG amounts are risk thresholds from studies and case reports. No advice to stop, reduce or replace existing medication with a herbal preparation. No paragraph implies that a psychiatric, psychotherapeutic, urological, gynecological or general practice assessment should be skipped or postponed. Observations from my consultations are marked as such. Research status: 16 and 17 September 2026.